Cutiss AG - Typewiser

Cutiss

About this project

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

We thoroughly enjoyed working with TypeWiser, it has been a real time-saver!

Daniela Marino

Topic
Bioengineering

Country
Switzerland

Website
cutiss.swiss

About the Company

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin.

Log-in / Sign-Up